{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T18:30:08Z","timestamp":1787941808348,"version":"build-2784847793"},"reference-count":19,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2017,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Omadacycline is a broad-spectrum aminomethylcycline in late-stage clinical development for the treatment of acute bacterial skin and skin structure infections and community-acquired pneumonia as an oral and an intravenous once-daily formulation. In this study, omadacycline and comparators were tested against 69,246 nonduplicate bacterial isolates collected prospectively during 2010 and 2011 from medical centers in Asia-Pacific (11,397 isolates), Europe (23,490 isolates), Latin America (8,038 isolates), and North America (26,321 isolates). Omadacycline was tested by broth microdilution following Clinical and Laboratory Standards Institute M07-A10 (2015) methods. A total of 99.9% of\n            <jats:named-content content-type=\"genus-species\">Staphylococcus aureus<\/jats:named-content>\n            isolates were inhibited by \u22642 \u03bcg\/ml of omadacycline (MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 0.12\/0.25 \u03bcg\/ml), including 100.0% of methicillin-susceptible\n            <jats:named-content content-type=\"genus-species\">S. aureus<\/jats:named-content>\n            isolates and 99.8% of methicillin-resistant\n            <jats:named-content content-type=\"genus-species\">S. aureus<\/jats:named-content>\n            isolates. Omadacycline potencies were comparable for\n            <jats:named-content content-type=\"genus-species\">Streptococcus pneumoniae<\/jats:named-content>\n            (MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 0.06\/0.06 \u03bcg\/ml), viridans group streptococci (MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 0.06\/0.12 \u03bcg\/ml), and beta-hemolytic streptococci (MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 0.06\/0.12 \u03bcg\/ml) regardless of species and susceptibility to penicillin. Omadacycline was active against\n            <jats:named-content content-type=\"genus-species\">Enterobacteriaceae<\/jats:named-content>\n            and was most active against\n            <jats:named-content content-type=\"genus-species\">Escherichia coli<\/jats:named-content>\n            (MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 0.5\/2 \u03bcg\/ml),\n            <jats:named-content content-type=\"genus-species\">Enterobacter aerogenes<\/jats:named-content>\n            (MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 2\/4 \u03bcg\/ml),\n            <jats:named-content content-type=\"genus-species\">Klebsiella oxytoca<\/jats:named-content>\n            (MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 1\/4 \u03bcg\/ml), and\n            <jats:named-content content-type=\"genus-species\">Citrobacter<\/jats:named-content>\n            spp. (MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 1\/4 \u03bcg\/ml). Omadacycline was active against\n            <jats:named-content content-type=\"genus-species\">Haemophilus influenzae<\/jats:named-content>\n            (MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 1\/1 \u03bcg\/ml) regardless of \u03b2-lactamase status and against\n            <jats:named-content content-type=\"genus-species\">Moraxella catarrhalis<\/jats:named-content>\n            (MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 0.12\/0.25 \u03bcg\/ml). The potent activity of omadacycline against Gram-positive and Gram-negative bacteria indicates that omadacycline merits further study in serious infections in which multidrug resistance and mixed Gram-positive and Gram-negative infections may be a concern.\n          <\/jats:p>","DOI":"10.1128\/aac.00018-17","type":"journal-article","created":{"date-parts":[[2017,2,22]],"date-time":"2017-02-22T01:30:22Z","timestamp":1487727022000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":62,"title":["Surveillance of Omadacycline Activity against Clinical Isolates from a Global Collection (North America, Europe, Latin America, Asia-Western Pacific), 2010-2011"],"prefix":"10.1128","volume":"61","author":[{"given":"Michael A.","family":"Pfaller","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"},{"name":"University of Iowa, Iowa City, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Huband","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R.","family":"Rhomberg","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2016.06.014"},{"key":"e_1_3_2_3_2","volume-title":"Transatlantic Taskforce on Antimicrobial Resistance: progress report","author":"Centers for Disease Control and Prevention","year":"2014","unstructured":"Centers for Disease Control and Prevention. 2014. Transatlantic Taskforce on Antimicrobial Resistance: progress report. Centers for Disease Control and Prevention, Atlanta, GA. https:\/\/www.cdc.gov\/drugresistance\/pdf\/tatfar-progress_report_2014.pdf."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000182"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/1744-8603-9-58"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature14098"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1086\/524891"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1086\/367622"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.2217\/fmb-2016-0100"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01536-15"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2011.06354.x"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki248"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01066-13"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01242-13"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00948-12"},{"key":"e_1_3_2_16_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u201410th ed","author":"CLSI","year":"2015","unstructured":"CLSI. 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u201410th ed. CLSI document M07-A10. CLSI, Wayne, PA."},{"key":"e_1_3_2_17_2","volume-title":"CLSI document M100-S26","author":"CLSI","year":"2016","unstructured":"CLSI. 2016. Performance standards for antimicrobial susceptibility testing: 26th informational supplement. CLSI document M100-S26. CLSI, Wayne, PA."},{"key":"e_1_3_2_18_2","unstructured":"EUCAST. 2016. Breakpoint tables for interpretation of MICs and zone diameters version 6.0 January 2016. http:\/\/www.eucast.org\/ast_of_bacteria\/previous_versions_of_documents\/."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2015.12.002"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)00065-7"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00018-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00018-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:54:32Z","timestamp":1645476872000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00018-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["10.1128\/AAC.00018-17"],"URL":"https:\/\/doi.org\/10.1128\/aac.00018-17","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"2017-01-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-02-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-04-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00018-17"}}